Results
1 -
10 of
14Zhang Xin, Lv Peng-Cheng, Li Dong-Dong, Zhang Wei-Ming, Zhu Hai-Liang.
Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead, Med. Chem. Commun., 2015 Histone deacetylase inhibitors in the treatment for multiple myeloma, International Journal of Hematology Histone deacetylase inhibitors in multiple myeloma: from bench to bedside, International Journal of Hematology The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimeru2019s disease, Translational Neurodegeneration Treatment of Patients in Third Relapse and Beyond Including Double-Refractory Disease, Personalized Therapy for Multiple Myeloma Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors, Cancer and Metastasis Reviews The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimeru2019s disease model, Cell Death & Disease HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells, Medical Oncology Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling, Tumor Biology Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcotu2013Marieu2013Tooth Disease, Neurotherapeutics